AI Insight
A study published in the American Journal of Psychiatry investigated whether low-dose buprenorphine could extend the therapeutic effects of ketamine on suicidal ideation in adults diagnosed with major depressive disorder. Results indicate that administering low-dose buprenorphine following a single ketamine infusion significantly prolonged reductions in suicidal ideation compared to ketamine alone. This suggests a potential pharmacological strategy for bridging the short-lived antidepressant and antisuicidal effects typically associated with ketamine treatment.
Why it matters
Suicidal ideation in major depressive disorder remains difficult to manage with standard treatments, and ketamine's effects are known to be transient, often lasting only days. If confirmed by larger trials, this combination approach could offer clinicians a more sustainable short-term intervention for patients at acute suicide risk.
New research published in the American Journal of Psychiatry finds that low-dose buprenorphine, given after a single ketamine infusion, significantly sustained reductions in suicidal ideation in adults with major depressive disorder.
Source: New research finds low-dose buprenorphine may help sustain ketamine's benefits for suicidal ideation